Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 2
2012 1
2013 1
2016 1
2018 2
2020 2
2021 5
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin.
Gausi K, Mugerwa H, Siccardi M, Montanha MC, Lamorde M, Wiesner L, D'Avolio A, McIlleron H, Wilkins E, De Nicolò A, Maartens G, Khoo S, Kityo C, Denti P, Waitt C. Gausi K, et al. Clin Infect Dis. 2023 Nov 20:ciad700. doi: 10.1093/cid/ciad700. Online ahead of print. Clin Infect Dis. 2023. PMID: 37982585 Free article.
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
Gausi K, Chirehwa M, Ignatius EH, Court R, Sun X, Moran L, Hafner R, Wiesner L, Rosenkranz SL, de Jager V, de Vries N, Harding J, Gumbo T, Swindells S, Diacon A, Dooley KE, McIlleron H, Denti P. Gausi K, et al. J Antimicrob Chemother. 2022 Aug 25;77(9):2489-2499. doi: 10.1093/jac/dkac188. J Antimicrob Chemother. 2022. PMID: 35678468 Free PMC article.
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Kengo A, et al. Among authors: gausi k. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850738 Free PMC article. Clinical Trial.
Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization.
Ali AM, Gausi K, Jongo SA, Kassim KR, Mkindi C, Simon B, Mtoro AT, Juma OA, Lweno ON, Gwandu CH, Bakari BM, Mbaga TA, Milando FA, Hamad A, Shekalaghe SA, Abdulla S, Denti P, Penny MA. Ali AM, et al. Among authors: gausi k. Antimicrob Agents Chemother. 2022 May 17;66(5):e0169621. doi: 10.1128/aac.01696-21. Epub 2022 Apr 25. Antimicrob Agents Chemother. 2022. PMID: 35465706 Free PMC article.
Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits.
Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant GJ, Kaya F, Gengenbacher M, Van N, Degefu Y, Nacy C, Aldridge BB, Carter CL, Denti P, Dartois V. Egbelowo O, et al. Among authors: gausi k. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0002421. doi: 10.1128/AAC.00024-21. Epub 2021 Aug 17. Antimicrob Agents Chemother. 2021. PMID: 34228540 Free PMC article.
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Sekaggya-Wiltshire C, Nabisere R, Musaazi J, Otaalo B, Aber F, Alinaitwe L, Nampala J, Najjemba L, Buzibye A, Omali D, Gausi K, Kengo A, Lamorde M, Aarnoutse R, Denti P, Dooley KE, Sloan DJ. Sekaggya-Wiltshire C, et al. Among authors: gausi k. Clin Infect Dis. 2023 Feb 8;76(3):e910-e919. doi: 10.1093/cid/ciac585. Clin Infect Dis. 2023. PMID: 35861296 Free PMC article. Clinical Trial.
25 results